New Stock Debut | HAIXI PHARMA listed on its first day with an opening increase of 18.02%, with four core generic drugs contributing over 90% of its revenue
I'm PortAI, I can summarize articles.
HAIXI PHARMA listed on its first day, opening up 18.02%, with a share price of HKD 86.40, issuing 11.5 million shares and net fundraising of approximately HKD 940 million. The current stock price is HKD 102, with a trading volume of HKD 142 million. The company's core generic drugs contribute over 90% of its revenue, with expected revenue of HKD 425 million in 2024. Its innovative drug pipeline includes several drugs under research, with the fastest, C019199, expected to enter Phase III trials in the second half of the year
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments